What You Should Know:
– Glooko, a provider of remote patient monitoring and digital health solutions for diabetes and other chronic conditions, today announced it has acquired xbird, a German-based health AI company developing JITAI ( Just In Time Adaptive Intervention) technologies to support patients and their providers in predicting behavior and managing diabetes.
– The addition of xbird expands Glooko’s advanced analytics capabilities and tools, further broadening Glooko’s platform offerings.
Xbird Background
Using the latest AI and machine learning, xbird’s technology has the capability of identifying health risks for people with diabetes by interpreting medical and behavioral data in a targeted manner and providing customized recommendations and behavioral nudges. Sensors via smartphones and wearables record a user’s movements and analyze the data to create individualized behavioral profiles and personalized nudges to change patient behavior and lifestyle decisions.
Why It Matters
Approximately 537 million adults are living with diabetes worldwide, with 9.5 million in Germany (15.3% of the population) and the numbers continue to rise. It is ranked in the top 10 global countries with the fastest growth in diabetes. Additionally, almost one in two people in Germany over 15 years report living with two or more chronic conditions (versus approximately one-third of people worldwide). According to the European Observatory on Health Systems and Policies, one in six adults are considered to be obese in Germany.
Post-Acquisition Plans
Glooko will integrate the xbird JITAI digital coaching software with its established platform which is used daily by more than 7500 clinics globally and over 1M users. Glooko plans to enable users of their platform globally to utilize these solutions to better manage their diabetes and related chronic conditions.
Sebastian Sujka, Chief Executive Officer and Co-Founder of xbird stated, “xbird and Glooko are a great fit. We share a commitment to providing solutions that address multiple chronic conditions, delivering measurable outcomes, and we have a common mission to broadly serve all patients in need. Our goal is to continue the design of digital health solutions for those living with these conditions and to make our capabilities accessible to as many patients as possible.” Mr. Sujka will join Glooko as the Managing Director of Glooko GmbH, along with all of the xbird staff.
Financial details of the acquisition were not disclosed.
